RAD ONC FREEDOM Oncology Pain

The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.

NCT Number	NCT07605546
Lead Sponsor	Jonsson Comprehensive Cancer Center Collaborators: Brainlab AG
Conditions	Cancer Pain
Enrollment	19 participants
Start Date	2026-06-09
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-08